Skip to main content

Judd Wendell Moul, MD

James H. Semans, M.D. Professor of Urologic Surgery, in the School of Medicine
Professor of Surgery
Professor in Anesthesiology
Office: 1573 White Zone, Duke South, Durham, NC 27710
Campus Mail: DUMC Box 3707 Med Ctr, Durham, NC 27710

Dr Judd Moul joined the Duke faculty in mid 2004 after a career in the US Army Medical Corps mainly at Walter Reed Army Medical Center.  He is a retired colonel and a noted researcher and clinician in the area of prostate cancer and is a urologic oncologist. He served as the division chief of Duke Division of Urology from 2004 to 2011 and was named the James H Semans MD Professor of surgery in 2009 becoming Duke's first named endowed chair for urology.  He was awarded the Gold Cystoscope Award from the American Urologic Association as well as Castle Connelly Physician of the year for Clinical Medicine in 2009.  He has performed more than 1300 radical prostatectomies since joining the Duke faculty and is committed to outcomes research on this series and in other areas of prostate cancer.  He served as the Editor for Prostate Cancer and Prostatic Dissease, a Nature Medicine journal, for more than a decade and is a popular speaker and lecturer having been visiting professor and keynote speaker throughout the US and the World.  He is very committed to training residents and mentoring students and trainees. 

Education and Training

  • Fellowship, Urologic Oncology, Duke University, 1988 - 1989
  • Residency, Urology, Walter Reed Army Medical Center, 1983 - 1987
  • Residency, Surgery, Walter Reed Army Medical Center, 1982 - 1983
  • M.D., Thomas Jefferson University, 1982
  • B.S., Pennsylvania State University, 1979

Publications

Moul, Judd W. “Most Men With Clinically Important Localized Prostate Cancer Deserve First-Line Open or Robotic Radical Prostatectomy.” Oncology New York 31, no. 11 (November 1, 2017): 830-+.

Scholars@Duke

Qi, Robert, Wen-Chi Foo, Michael N. Ferrandino, Leah G. Davis, Sitharthan Sekar, Thomas A. Longo, Ghalib Jibara, Tracy Han, Ilhan Gokhan, and Judd W. Moul. “Over half of contemporary clinical Gleason 8 on prostate biopsy are downgraded at radical prostatectomy..” Can J Urol 24, no. 5 (October 2017): 8982–89.

Scholars@Duke

Tay, K. J., R. T. Gupta, J. Holtz, R. K. Silverman, E. Tsivian, A. Schulman, J. W. Moul, and T. J. Polascik. “Does mpMRI improve clinical criteria in selecting men with prostate cancer for active surveillance?.” Prostate Cancer Prostatic Dis 20, no. 3 (September 2017): 323–27. https://doi.org/10.1038/pcan.2017.20.

Full Text

Schulman, Ariel A., Christina Sze, Efrat Tsivian, Rajan T. Gupta, Judd W. Moul, and Thomas J. Polascik. “The Contemporary Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Prostate Cancer..” Curr Urol Rep 18, no. 7 (July 2017). https://doi.org/10.1007/s11934-017-0699-2.

Full Text

Stone, Steven, Matthew R. Cooperberg, Darl D. Flake, John W. Davis, Judd W. Moul, Jonathan David Tward, and Michael K. Brawer. “Evaluation of microarrays for measuring cell cycle progression (CCP) gene expression..” In Journal of Clinical Oncology, 35:e16566–e16566. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.e16566.

Full Text

Madden-Fuentes, Ramiro Jose, Bridget F. Koontz, Michael R. Harrison, Daniel J. George, Brittany Davidson, Brian F. Gilmore, Judd W. Moul, Christopher Mantyh, and Andrew C. Peterson. “How Can We Effectively Address the Medical and Psychological Concerns of Survivors of Pelvic Malignancies?.” Oncology (Williston Park) 31, no. 4 (April 15, 2017): 286–94.

Scholars@Duke

Madden-Fuentes, RJ, Koontz, BF, Harrison, MR, George, DJ, Davidson, B, Gilmore, BF, Moul, JW, Mantyh, C, and Peterson, AC. "How Can We Effectively Address the Medical and Psychological Concerns of Survivors of Pelvic Malignancies?." Oncology (Williston Park, N.Y.) 31, no. 4 (April 2017): 286-294. (Review)

Scholars@Duke

Moul, Judd W., John A. McLane, Stuart Atkinson, and Raoul S. Concepcion. “Head-to-head pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprorelin acetate formulations in male patients..” In Journal of Clinical Oncology, 35:e589–e589. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.6_suppl.e589.

Full Text

Shore, Neal D., Franklin Chu, Judd Moul, Daniel Saltzstein, Raoul Concepcion, John A. McLane, Stuart Atkinson, Alex Yang, and E David Crawford. “Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer..” Bju Int 119, no. 2 (February 2017): 239–44. https://doi.org/10.1111/bju.13482.

Full Text

Pages